CVRx (CVRX) Insider Ownership : 0.81 % (As of May. 21, 2024)

View and export this data going back to 2021. Start your Free Trial

What is CVRx Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CVRx's insider ownership is 0.81%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CVRx's Institutional Ownership is 15.56%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CVRx's Float Percentage Of Total Shares Outstanding is 60.93%.

CVRx Insider Ownership Historical Data

The historical data trend for CVRx's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx Insider Ownership Chart

CVRx Historical Data

The historical data trend for CVRx can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Insider Ownership	0.77	0.76	0.79	0.79	0.79	0.80	0.83	0.83	0.84	0.81

CVRx Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

CVRx (CVRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445

Website

https://www.cvrx.com

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Executives

Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro	officer: Chief Marketing Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes	director	2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain	director	C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer	officer: SVP, U.S. Sales	9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan	director	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P	10 percent owner
Nea Partners 10 L P	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo	director	100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim	officer: Chief Financial Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall	officer: Chief Strategy Officer and Sec	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding	officer: VP of Reg. Affairs and QA	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle	officer: VP of Global Clinical Research	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared	director, officer: Chief Executive Officer	9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445